A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects

Healthy Subjects Clinical Trial

Official title:

A Single-Centre, Single-Administration, Dose-Escalation Study and A Single-Centre, Randomized, Open-Label, Two-cycle Crossover Food Effect Study of SKLB1028 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05109663
• Other study ID #: HA114-CSP-006
• Status: Completed
• Phase: Phase 1
• Start date: April 14, 2021
• Est. completion date: June 30, 2021

Study information

• Verified date: January 2021
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.

Description:

The study was divided into 2 parts. Part 1(Dose Escalation) included 2 cohorts (Cohort 1 and Cohort 2) and subjects received a single oral dose of SKLB1028 50 or 100 mg on Day 1. In Part 2 (Food Effect) included 2 cohorts (Cohort A and Cohort B), subjects received a single oral dose of SKLB1028 150 mg in a fasting and a fed state, with a 10-day washout period between the 2 doses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: June 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

-

Healthy subjects:

1. Male or female subjects aged 18 to 45 (including 18 and 45 years old), and the proportion of single sex should not be less than 1/3;

2. Male weight =50.0 kg, female weight =45.0 kg; body mass index (BMI) 18-24 kg/m^2 (inclusive);

3. Normal or abnormal results without clinically significance on all tests including medical history, physical examination, vital signs, clinical laboratory tests (routine blood test, blood biochemistry, routine urine test, coagulation function), etc;

4. Subjects are willing to use effective non-hormonal contraceptives such as condom and intrauterine device without medication, and not allowed to donate sperm from screening to the 6 months after the last dose administration unless permanent contraception has been taken, such as bilateral tubal ligation and vasectomy;

5. Voluntarily sign the informed consent form, and be willing to comply with the protocol.

Exclusion Criteria:

1. Previous or current clear psychiatric/neurological systems diseases; previous or current severe diseases, such as cardiovascular, liver and kidney, endocrine, respiratory, hematological, digestive and immune systems diseases; previous or current malignant tumors;

2. Allergic constitution, including a history of allergy to one or more medications, or other known severe allergic reactions;

3. Inability to swallow oral medications; previous or current diseases that may affect the absorption, distribution, metabolism, or excretion of the drug, or affect the evaluation of efficacy and safety of the drug, such as active bowel disease, partial or complete bowel obstruction and chronic diarrhea;

4. Previous or current diseases such as gastrointestinal ulcer and related bleeding;

5. Abnormalities of clinical significance in electrocardiogram (such as QTcF=450 ms in males or =470 ms in females) or history of prolonged QTcF interval;

6. Any abnormalities of clinical significance in vital signs;

7. Any positive test result of hepatitis B surface antigen or hepatitis C virus antibody, or anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;

8. Use of any prescription drugs, over-the-counter drugs, biologicals, proprietary Chinese medicine, herbal medicine, dietary supplements, health products, long-acting oral contraceptives or implantable long-acting contraceptives within 2 weeks prior to screening;

9. Use of any strong inhibitors or inducers of CYP3A4, CYP2C8 or P-gp within 2 weeks prior to screening;

10. Average daily intake of alcohol more than 14 units (14 units ˜285 mL of beer, or 25 mL of liquor, or 150 mL of wine) within 4 weeks prior to signature of informed consent, or a positive ethanol breath test at screening;

11. Smoking more than 5 cigarettes per day within 6 months prior to screening;

12. History of drug abuse within 1 year prior to screening, or positive urine drug screen at screening;

13. Average daily consumption of too much caffeinated beverages and foods or that might affect drug metabolism, such as coffee (over 1100 mL per day), tea (over 2200 mL per day), cola (over 2200 mL per day), functional beverage (over 1100 mL per day), chocolate (over 510 g per day) within 4 weeks prior to screening;

14. Consumption of cigarettes, alcohol or methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 h before the administration, or those who have special dietary requirements and cannot follow a uniform diet;

15. Difficulty in venous blood collection or subjects with a history of fainting needle or blood;

16. Blood donation (or blood loss) =200 mL within 4 weeks prior to the screening, or who have a blood donation plan during the entire study or within 1 months after the study;

17. Subjects who have previously undergone surgery within 6 months prior to screening or who have a scheduled surgical plan (including cosmetic surgery, dental surgery and oral surgery) during the study period;

18. Participation in another clinical trial within 3 months before screening (whichever is administrated);

19. Any condition that the investigator considers inappropriate for participation in the study.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• SKLB1028
SKLB1028, capsule, oral

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events (TEAEs)	TEAEs were assessed by CTCAE v5.0 in Part 1	Throughout the study period, with an average of 10 days.
Primary	Maximum plasma concentration (Cmax) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Time to Cmax (Tmax) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Terminal-elimination half-life (T1/2) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Apparent volume of distribution (Vz/F) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Primary	Apparent clearance (CLz/F) of SKLB1028 in Part 2		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Maximum plasma concentration ( Cmax) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Area under the concentration-time curve from time 0 to infinity (AUCinf) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Time to Cmax (Tmax) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Terminal-elimination half-life (T1/2) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Apparent volume of distribution (Vz/F) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Apparent Clearance (CLz/F) of SKLB1028 in Part 1		Pre-dose and multiple timepoints up to 144 hours post-dose
Secondary	Number of participants with TEAEs	TEAEs were assessed by CTCAE v5.0 in Part 2	Throughout the study period, with an average of 20 days